Adults taking antidepressants are not at greater risk of suicidal thoughts or behaviour, but young adults aged less than 25 years of age are at an increased risk, similar to that seen in children and adolescents, finds research published on bmj.com today.
The paper expands on analyses first made available by the US Food and Drug Administration (FDA) two years ago. It includes different methods, additional explorations of the data, and an expanded discussion of the implications of the findings.
Previous studies have shown that antidepressant drugs are linked with an increased risk of suicidal behaviour and thoughts in children and adolescents, particularly in the early stages of treatment. This led the FDA to add a black box warning to antidepressants in 2005 and to examine trials of antidepressants in adults to look for similar effects.
Dr Marc Stone and colleagues from the FDA asked eight manufacturers of antidepressant products to provide data on suicidal thinking and behaviour from published and unpublished randomised trials on antidepressants in adults. They reviewed data from 372 placebo controlled trials involving nearly 100,000 patients.
Findings showed eight completed suicides, 134 suicide attempts, 10 patients who had made preparations without attempting suicide, and 378 patients who had thoughts about suicide but had not acted on them.
Overall, drug type and diagnostic category made little difference to risk of suicidal behaviour, with the exception of some differences among selective serotonin reuptake inhibitors (SSRIs).